- Login
- Register & Subscribe
- Sprache: EN FR DE
Research & University News
Circassia completes ragweed vaccine study
Tuesday 13 March 2012
Circassia Ltd of the UK has completed a Phase 2 study of its T-cell vaccine for ragweed allergy showing a significant reduction in symptoms, the company said. The company is backed by venture capital with Imperial Innovations holding 18.4%.
Location
United Kingdom
Basilea reports on US eczema trial
Monday 12 March 2012
Basilea Pharmaceutica Ltd of Switzerland said that its Phase 3 US trial for the investigational compound alitretinoin for severe chronic hand eczema achieved ‘clear’ or ‘almost clear’ hands for 40% of patients, thus meeting the trial’s primary endpoint.
Location
Switzerland
Phase 3 trial starts for ulcerative colitis immunotherapy
Wednesday 7 March 2012
InDex Pharmaceuticals AB, a privately-held Swedish immunotherapy company, is starting a Phase 3 trial of Kappaproct, which has performed well in earlier tests in treating steroid-resistant ulcerative colitis patients.
Location
Sweden
Big Pharma should outsource discovery
Thursday 9 February 2012
In seeking to increase R&D productivity, Big Pharma should consider outsourcing all of its discovery activity and focus instead on building capacity in translational medicine, Simon Moroney, the MorphoSys chief executive, told a meeting in London.
Location
United Kingdom
ArGEN-X advances anti c-Met antibody
Thursday 9 February 2012
Venture-capital backed ArGEN-X BV of the Netherlands said that it has advanced a third therapeutic antibody candidate into preclinical development, in this instance an antibody targeting the c-Met signalling pathway which is implicated in many cancers.
Location
Netherlands
Enrolment stopped in four antibiotic studies
Tuesday 7 February 2012
Anacor Pharmaceuticals Inc said that enrolment of patients into four studies of a new agent against Gram-negative bacteria, GSK052, has been stopped pending investigation of a microbiologial finding in a small number of patients.
Location
United States
Agennix stops trial in severe sepsis
Thursday 2 February 2012
Agennix AG of Germany has stopped further enrollment and treatment in a Phase 2/3 trial of talactoferrin, a genetically-engineered form of the human protein, lactoferrin, on safety grounds. The drug was being studied in sepsis.
Location
Germany
Gene mutation linked with lymphoedema
Sunday 29 January 2012
A research consortium, led by investigators at St George’s, University of London, has reported discovering a new gene, the fourth in a series, to be associated with lymphoedema, a swelling that arises from an impaired lymphatic system.
Location
United Kingdom
Immune regulation mechanism reported
Saturday 28 January 2012
A novel immune mechanism that could play a role in the treatment of a wide variety of diseases has been described in the journal Science. The finding was made by a team led by Eric Vivier, scientific co-founder of Innate Pharma SA of France.
Location
France
Heptares’ technology highlighted in journal
Friday 27 January 2012
Two papers in the Journal of Medicinal Chemistry have highlighted technology developed by scientists at Heptares Therapeutics Ltd aimed at generating new leads for drugs that target the G protein-coupled receptor (GPCR) family of proteins.
Location
United Kingdom
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013